603367 Cisen Pharmaceutical
- 16.57
- -0.05-0.30%
Cisen Pharmaceutical News
Express News | Chenxin Pharmaceutical: Beihai Chenxin plans to transfer the company's 454.14 million tradable shares with unlimited sales conditions to Mr. Han Yanzhen
Chenxin Pharmaceutical (603367.SH): R&D investment in 2023 accounts for more than 8% of revenue
Gelonghui, May 9丨Chen Xin Pharmaceutical (603367.SH) said at the performance briefing that Chen Xin Pharmaceutical adheres to the development concept of “introducing innovation, honesty and trustworthiness” and has always used scientific and technological innovation as the driving force for sustainable development. In 2023, R&D investment accounted for more than 8% of revenue, which strongly supported the company's transformation, upgrading and sustainable development. At the same time, the company adheres to the combination of independent innovation and cooperative innovation. On the basis of independent research and development, the company attaches great importance to various collaborations. It has successively cooperated with Georgia State University in the United States, Liverpool University in the UK, Peking University, the Academy of Military Medical Sciences, China Pharmaceutical University, and Shandong
Express News | Chenxin Pharmaceutical: Beihai Chenxin plans to reduce its shareholding by no more than 1%
The actual controller of Chenxin Pharmaceutical (603367.SH) completed an increase of 1.8751 million shares
Chenxin Pharmaceutical (603367.SH) announced that Du Zhenxin, the actual controller, chairman and general manager of the company, has passed through Shanghai...
Chenxin Pharmaceutical (603367): Benefiting from medical recovery and new product development, the company is expected to develop steadily
Incident: The company released its report for the first quarter of 2024. 2024Q1 achieved revenue and net profit to mother of 1,149 million yuan and 163 million yuan respectively, up 1.28% and 4.50% year-on-year respectively. Big infusion
Cisen Pharmaceutical Names Chief Financial Officer
Cisen Pharmaceutical (SHA:603367) appointed one of its directors, Xu Xinbing, as chief financial officer, according to the company's filing on the Shanghai Stock Exchange. Xu will take over from Du Zh
Chenxin Pharmaceutical (603367.SH) announced its 2023 annual results, with net profit of 521 million yuan, an increase of 48.97% over the previous year
Chenxin Pharmaceutical (603367.SH) disclosed its 2023 annual report, and the company achieved 44 revenue in 2023...
Cisen Pharmaceutical's (SHSE:603367) Earnings Trajectory Could Turn Positive as the Stock Rises 6.9% This Past Week
For many, the main point of investing is to generate higher returns than the overall market. But in any portfolio, there will be mixed results between individual stocks. So we wouldn't blame long te
Chen Xin Pharmaceutical (603367.SH): Fodu Pharmaceutical plans to apply for listing on the Beijing Stock Exchange
Gelonghui, January 3, 丨 Chenxin Pharmaceutical (603367.SH) announced that the company held the 26th meeting of the 4th board of directors and the 25th meeting of the 4th board of supervisors on January 3, 2024. The meetings separately reviewed and passed the “Proposal on the Holding Subsidiary Shandong Chenxin Fodu Pharmaceutical Co., Ltd. to apply for listing on the Beijing Stock Exchange”. The board of directors agreed to the holding subsidiary Fodu Pharmaceutical planning to apply for listing on the Beijing Stock Exchange.
Cisen Pharmaceutical (SHSE:603367) Has A Rock Solid Balance Sheet
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to consider debt, when you think about how risky any given stock is, because too much
Chenxin Pharmaceutical (603367.SH): Terminate plans to spin-off the holding subsidiary Fodu Pharmaceutical to list on the main board of the Shenzhen Stock Exchange and apply for listing on the new third board
On December 1, Gelonghui (603367.SH) announced that Chenxin Pharmaceutical () announced that the board of directors agreed to stop planning for the spin-off of the holding subsidiary Shandong Chenxin Fodu Pharmaceutical Co., Ltd. (“Fodu Pharmaceutical”) to the main board of the Shenzhen Stock Exchange, and agreed that Fodu Pharmaceutical should apply for listing on the National SME Share Transfer System (New Third Board). After listing, Fodu Pharmaceutical will seek an opportunity to go public on the Beijing Stock Exchange according to the future capital market environment and strategic development needs.
Chenxin Pharmaceutical (603367.SH): The ninth batch of collected Volgrebo sugar tablets was not selected
Gelonghui November 20 - Chenxin Pharmaceutical (603367.SH) said at the performance briefing that the ninth batch of collected Volgrebo sugar tablets was not selected, and that the company will continue to optimize costs, improve product competitiveness, and stand out in subsequent collection.
Cisen Pharmaceutical Co., Ltd.'s (SHSE:603367) Market Cap Dropped CN¥397m Last Week; Private Companies Bore the Brunt
Key Insights Significant control over Cisen Pharmaceutical by private companies implies that the general public has more power to influence management and governance-related decisions A total of 4 i
Chenxin Pharmaceutical (603367.SH) expects net profit of 370 million yuan from January to September, an increase of about 26.71% over the previous year
Chenxin Pharmaceutical (603367.SH) announced that from January to September 2023, after preliminary estimates, the company was able to belong to...
Chenxin Pharmaceutical (603367.SH): The company's current drugs for treating liver disease include adefovir tablets, etc.
Glonghui September 5 | Chenxin Pharmaceutical (603367.SH) said at the performance briefing on September 5, 2023, that the company's current drugs for treating liver disease include adefovir tablets, diamine glycyrrhizinate injections, matrine sodium chloride injections, and thiopronin injections.
Are Cisen Pharmaceutical Co., Ltd.'s (SHSE:603367) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?
With its stock down 21% over the past three months, it is easy to disregard Cisen Pharmaceutical (SHSE:603367). It is possible that the markets have ignored the company's differing financials and de
Chenxin Pharmaceutical (603367.SH) announced first-half results and net profit of 264 million yuan, up 43.52% year-on-year
Chenxin Pharmaceutical (603367.SH) disclosed the 2023 semi-annual report. The company achieved operating income of 2 during the reporting period...
Cisen Pharmaceutical (SHSE:603367) Stock Falls 6.1% in Past Week as Five-year Earnings and Shareholder Returns Continue Downward Trend
For many, the main point of investing is to generate higher returns than the overall market. But in any portfolio, there will be mixed results between individual stocks. At this point some sharehold
Chenxin Pharmaceutical (603367.SH): Volglebose tablets obtained a drug registration certificate
Gelonhui, June 13, 丨 Chenxin Pharmaceutical (603367.SH) announced that the company has received the “Drug Registration Certificate” (certificate number: 2023S00722) and the “Drug Registration Certificate” (certificate number: 2023S00726) for the voglebose tablets (certificate number:) and the cabectocin injection (certificate number:) issued with approval from the China Drug Administration. Volglipose tablets are oral hypoglycemic agents. As an α-glucosidase inhibitor, they inhibit the disaccharide hydrolase (α-glucosidase) that breaks down disaccharides into monosaccharides in the intestines, thereby delaying the digestion and absorption of sugar, thereby improving postprandial hyperglycemia.
Chenxin Pharmaceutical (603367.SH): Plans to spin-off the subsidiary Fudu Pharmaceutical to be listed on the main board of the Shenzhen Stock Exchange
Gelonghui, June 9丨Chenxin Pharmaceutical (603367.SH) announced that it plans to spin-off its subsidiary Fudu Pharmaceutical to be listed on the main board of the Shenzhen Stock Exchange. After the spin-off is completed, Chenxin Pharmaceutical's shareholding structure will not change, and it is still the controlling shareholder of Fodu Pharmaceutical. This spin-off will turn Fodu Pharmaceutical into an independent listing platform with eye preparations as the main business under the company. Enhancing capital strength through listing financing will help Fudu Pharmaceutical enhance the continued profitability and core competitiveness of the ophthalmic formulation business, strengthen the level of research and development, and enhance its brand image.
Analysis
Price Target
No Data
